FDA Rejects Disc Medicine's Drug for Rare Sunlight Sensitivity Disorder, Shares Plunge
Disc Medicine's bitopertin gets turned down by FDA for treating EPP, a painful genetic condition making skin ultra-sensitive to sun.
/ 4 items
#IRON↓
FDA Delays Decisions on Lilly's Obesity Pill and Other Fast-Track Drug Reviews
FDA extends review timelines for Eli Lilly's obesity pill Orforglipron and three other priority voucher drugs, despite promises of accelerated 1-2 month reviews under new program.
Disc Medicine Stock Drops Amid FDA Official's Questions on Drug Effectiveness
Disc Medicine (IRON) shares fall 14% after FDA official questions bitopertin's effectiveness for rare blood disorder, though analysts maintain buy ratings and approval pathway optimism.
Disc Medicine Gets FDA Fast-Track Voucher for Rare Skin Disease Treatment
Disc Medicine receives FDA's Commissioner's National Priority Voucher for bitopertin, accelerating approval timeline to 1-2 months for EPP patients who suffer severe sun sensitivity.